Given the known role of ZEB1 in tumor cells to induce EMT, stemness, and chemoresistance, combined targeting of ZEB1 in fibroblast and tumor cells might act synergistically to improve CRC therapy. This evidence concerns the gene ZEB1 and colorectal carcinoma.